SIRPA, BTN3A1, and TDO2 in osteosarcoma: a prognostic triad with therapeutic implications from integrated genomic and...

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• Prognostic implications of immune checkpoints in osteosarcoma (OS) are poorly understood.
• Lack of reliable biomarkers hinders personalized treatment and outcome prediction in OS.
• Immune checkpoints play a crucial role in tumor immune evasion and therapeutic response.

Purpose of the Study:

• To investigate the prognostic value of specific immune checkpoints (BTN3A1, SIRPA, TDO2) in osteosarcoma.
• To develop a prognostic risk model based on these immune checkpoints.
• To explore the correlation between these immune checkpoints and drug sensitivity.

Main Methods:

• Utilized data from the TARGET database and clinical follow-up data.
• Performed univariate Cox regression and least absolute shrinkage and selection operator (LASSO) analyses.
• Developed a three-immune-checkpoint genetic prognostic risk model and conducted drug sensitivity analysis.

Main Results:

• BTN3A1, SIRPA, and TDO2 were identified as significant prognostic indicators in osteosarcoma.
• The developed risk model showed differential prognostic implications across clinical subgroups.
• Correlation was found between BTN3A1, SIRPA, TDO2 and the efficacy of hydroxyurea and docetaxel.

Conclusions:

• Established a framework for using immune checkpoints as prognostic biomarkers in osteosarcoma.
• SIRPA demonstrated significant prognostic value in a clinical cohort, suggesting its potential as an immunotherapy target.
• Findings support the role of immune checkpoints in enhancing personalized treatment strategies for osteosarcoma patients.